Lilly’s revenue soars 48%, driven by demand for its GLP-1s
1 min read
The coverage · 2 reports
- MarketWatchFirst reportLilly’s revenue soars 48%, driven by demand for its GLP-1s ↗
- Yahoo FinanceLatestEli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares Pop ↗
The story
Eli Lilly posted a 48% jump in revenue, with the beat attributed to demand for Mounjaro (Type 2 diabetes) and Zepbound (weight loss) that exceeded expectations. SEC filing data shows full-year revenue near $65.2B with year-over-year growth of 44.7%, a 31.7% net margin, and diluted EPS of $22.95 — figures that underscore how central the GLP-1 franchise has become to Lilly's overall business.
This matters because Lilly and Novo Nordisk have been racing to capture the obesity-drug market, widely viewed as one of the largest new pharmaceutical categories in decades. A 48% revenue print driven specifically by GLP-1 demand signals that supply constraints that have periodically capped sales may be easing, or that underlying prescription demand is simply outrunning prior guidance.
The setup going forward centers on durability: can Lilly sustain this growth rate as competition intensifies (including oral GLP-1 candidates and Novo's own pipeline), and does the current margin profile hold as manufacturing scales further. The bull case rests on demonstrated demand outstripping expectations; the bear case is the standard high-growth-stock tension — a beat this large raises the bar for future quarters, and any deceleration or new competitive/pricing pressure could weigh on shares even with strong fundamentals intact. Watch subsequent guidance commentary and capacity updates as the next signals.
The case — both sides
Revenue grew 48% YoY to roughly $65.2B with a 31.7% net margin and $22.95 diluted EPS, showing GLP-1 demand is not just meeting but exceeding expectations at scale.
A growth rate this extreme sets a materially higher bar for future quarters, and the summary itself frames this as demand simply catching up to expectations, which raises the risk of deceleration once comparisons normalize.
The house read
Two-sidedLLY posted 48% revenue growth on GLP-1 demand with $65.2B in FY revenue and 31.7% net margin — the question is whether this growth rate is sustainable or whether the beat simply raises forward expectations to a harder bar.
Wrong ifA beat-and-raise quarter like this often gets priced in fast; any hint of deceleration, supply normalization undercutting pricing, or competitive share loss to oral GLP-1 rivals could trigger a sharp reversal despite strong current fundamentals.
Published read · research, not advice